Drugs in development
The development of new drugs is a long and difficult process. Fewer than one or two compounds in 10,000 tested actually make it through to being licensed treatments. A potential new medicine may be rejected at any point in the development process on safety, efficacy or quality grounds. On average it will take 10-15 years for a new compound to get from the test-tube into the medicine cabinet.
The following drugs are currently under development:
It is important to remember that not all these drugs will complete the development process and be licensed for general use (or be recommended by NICE or SMC). It is also unlikely that any of these new treatments will be available before 2011.
- Treatments for relapsing/remitting MS
- Alemtuzumab
- BG00012
- Cladribine
- Daclizumab
- Fingolimod
- Laquinimod
- MBP8298
- Neurovax
- Rituximab
- Teriflunomide
- Tovaxin